|
|
|
| 
|
|
|
My Recent Searches
|
|
|
|
|
|
|
|
|
Ikena Oncology, Inc. (IKNA) |
|
|
$0.00 0.00 (0.00%) as of 4:30 Tue 11/30
|
|
Download |
|
|
| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
48,260,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$ - $ |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Ikena Oncology is a targeted oncology company developing medicines tailored to biomarker-defined patient groups. Co.'s programs are across the Hippo pathway, RAS pathway, and key immune signals in the tumor-microenvironment, with approaches to targeting both cancer driving targets and mechanisms of resistance to targeted therapies. Co.'s primary targeted oncology product candidate, IK-930, is an oral small molecule inhibitor of the transcriptional enhanced associate domain transcription factor in the Hippo signaling pathway. Co.'s clinical-stage programs also include product candidates in development to target immune signaling in the tumor microenvironment.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
504,450 |
| Total Sell Value |
$0 |
$0 |
$0 |
$2,256,040 |
| Total People Sold |
0 |
0 |
0 |
2 |
| Total Sell Transactions |
0 |
0 |
0 |
6 |
| End Date |
2024-02-15 |
2023-11-14 |
2023-05-16 |
2022-05-16 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Orbimed Genesis Gp Llc |
Director |
– • – |
2021-03-30 |
4/A |
A |
$0.00 |
$0 |
I/I |
5,586,311 |
157,288 |
|
- |
|
| Orbimed Genesis Gp Llc |
Director |
– • – |
2021-03-30 |
4/A |
B |
$16.00 |
$6,774,400 |
I/I |
423,400 |
91,014 |
2.1 |
- |
|
| Orbimed Genesis Gp Llc |
Director |
– • – |
2021-03-30 |
4/A |
A |
$0.00 |
$0 |
I/I |
1,513,486 |
42,614 |
|
- |
|
| Bonita David P |
Director |
– • – |
2021-03-30 |
4/A |
A |
$0.00 |
$0 |
I/I |
5,586,311 |
157,288 |
|
- |
|
| Bonita David P |
Director |
– • – |
2021-03-30 |
4/A |
B |
$16.00 |
$6,774,400 |
I/I |
423,400 |
91,014 |
2.1 |
- |
|
| Bonita David P |
Director |
– • – |
2021-03-30 |
4/A |
A |
$0.00 |
$0 |
I/I |
1,513,486 |
42,614 |
|
- |
|
| Stampacchia Otello |
Director |
– • – |
2021-03-30 |
4 |
A |
$16.00 |
$7,200,000 |
I/I |
450,000 |
2,249,123 |
|
- |
|
| Stampacchia Otello |
Director |
– • – |
2021-03-30 |
4 |
A |
$0.00 |
$0 |
I/I |
1,799,123 |
1,799,123 |
|
- |
|
| Bonita David P |
Director |
– • – |
2021-03-30 |
4 |
A |
$0.00 |
$0 |
I/I |
5,214,394 |
130,924 |
|
- |
|
| Bonita David P |
Director |
– • – |
2021-03-30 |
4 |
B |
$16.00 |
$6,774,400 |
I/I |
423,400 |
117,378 |
2.1 |
- |
|
| Bonita David P |
Director |
– • – |
2021-03-30 |
4 |
A |
$0.00 |
$0 |
I/I |
1,885,403 |
68,978 |
|
- |
|
| Atlas Venture Associates Opportunity I, Llc |
10% Owner |
– – • |
2021-03-30 |
4 |
A |
$0.00 |
$0 |
I/I |
4,750,361 |
749,634 |
|
- |
|
| Orbimed Genesis Gp Llc |
Director |
– • – |
2021-03-30 |
4 |
A |
$0.00 |
$0 |
I/I |
5,214,394 |
130,924 |
|
- |
|
| Orbimed Genesis Gp Llc |
Director |
– • – |
2021-03-30 |
4 |
B |
$16.00 |
$6,774,400 |
I/I |
423,400 |
117,378 |
2.1 |
- |
|
| Orbimed Genesis Gp Llc |
Director |
– • – |
2021-03-30 |
4 |
A |
$0.00 |
$0 |
I/I |
1,885,403 |
68,978 |
|
- |
|
| Formela Jean Francois |
Director |
– • – |
2021-03-30 |
4 |
A |
$0.00 |
$0 |
I/I |
4,750,361 |
749,634 |
|
- |
|
| Atlas Venture Associates Opportunity I, Llc |
10% Owner |
– – • |
2021-03-25 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
169,095 |
|
- |
|
| Tessier Maude |
Chief Business OfficerOfficer |
• – – |
2021-03-25 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
28,792 |
|
- |
|
| Formela Jean Francois |
Director |
– • – |
2021-03-25 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
169,095 |
|
- |
|
44 Records found
|
|
Page 2 of 2 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
